Table 3.
Men
|
Women
|
|||
---|---|---|---|---|
Survival | White patients (n=2494) | South Asian patients (n=190) | White patients (n=2563) | South Asian patients (n=146) |
Patients aged <75 | ||||
Survival: | ||||
30 days | 85 (83 to 87) | 85 (76 to 91) | 87 (84 to 90) | 91 (85 to 97) |
1 year | 70 (67 to 73) | 72 (64 to 80) | 68 (64 to 72) | 79 (71 to 87) |
2 years | 63 (60 to 66) | 66 (57 to 75) | 59 (55 to 63)* | 75 (65 to 85)* |
Survival to event (death or readmission):
|
|
|
||
30 days | 81 (80 to 82) | 82 (75 to 89) | 84 (81 to 87) | 88 (81 to 95) |
1 year | 51 (48 to 54) | 54 (44 to 64) | 51 (47 to 55) | 54 (44 to 64) |
2 years | 37 (34 to 40) | 35 (25 to 45) | 35 (31 to 39) | 37 (26 to 48) |
Patients aged ≥75 | ||||
Survival: | ||||
30 days | 77 (75 to 79) | 77 (67 to 87) | 78 (76 to 80) | 85 (75 to 95) |
1 year | 49 (46 to 52) | 62 (51 to 73) | 54 (52 to 56) | 62 (48 to 76) |
2 years | 38 (35 to 41) | 50 (36 to 64) | 43 (40 to 46) | 52 (36 to 68) |
Survival to event (death or readmission):
|
|
|
||
30 days | 74 (72 to 76) | 72 (61 to 83) | 77 (75 to 79) | 83 (73 to 93) |
1 year | 36 (34 to 38) | 37 (25 to 49) | 41 (39 to 43) | 44 (30 to 58) |
2 years | 22 (20 to 24) | 20 (8 to 32) | 25 (23 to 27) | 30 (16 to 44) |
Statistically significant difference.